Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Abilify

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Abilify was produced by Otsuka and Bristol-Myers Squibb.

3-in-1: A winning combination for Sevikar HCT

Communicating the value of Abilify (aripiprazole) in a changing NHS.

A new era in anticoagulation: The EU launch of Pradaxa

Communicating the value of Abilify (aripiprazole) in a changing NHS.

Launch of INCIVO

Communicating the value of Abilify (aripiprazole) in a changing NHS.

FDA panel backs Alexza’s inhaled antipsychotic drug

At the moment, agitation in psychotic patients is generally treated with injectable formulations of Eli Lilly's Zyprexa (olanzapine), Pfizer's Geodon (ziprasidone) and Bristol-Myers Squibb's Abilify (aripiprazole).

FDA starts review of Lundbeck’s antipsychotic aripiprazole

A marketing application in Europe is not expected until 2013. Otsuka originally developed aripiprazole and sells a once-daily tablet formulation under the Abilify brand name in collaboration with Bristol-Myers ... Otsuka estimates that Abilify will

[ Previous 5 results ] 8 9 10 11 12 13 14 15 16 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
Fearless Girl cover
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)...

Infographics